Quote:
Originally Posted by Ramrod
Chris. I was taught that in Uni by a GP, a surgeon and a neurologist in 3 separate classes 30 years ago and nothing has changed since ( I keep an eye on the literature from time to time).
It's common knowledge in the medical professions.
|
I guess the under reporting would be an issue if you took the Yellow Card data in isolation. However the MHRA works hard to account for the variables in the reporting system including the issue of under reporting. The MHRA discuss this here -
https://www.gov.uk/government/public...y-surveillance
Under reporting is an issue but once you have a handle of when and why potential adverse reactions are not reported, you can at least correct for it to some extent. It’s not ideal but the self reporting system most regulatory bodies including the MHRA use is the ‘least worst’ option for post-market surveillance